Skip to main content

Celcuity Inc.

corporate_fare Company Profile

Celcuity Inc.

CELC·NASDAQ·Life Sciences·CIK 0001603454

Celcuity Inc. is a clinical-stage biotechnology company developing targeted therapies for various solid tumor indications. Its primary therapeutic candidate is gedatolisib, a kinase inhibitor that targets the phosphatidylinositol 3-kinase (PI3K), serine/threonine-protein kinase protein kinase B (AKT), and mechanistic target of rapamycin (mTOR) pathway. Gedatolisib comprehensively inhibits the PI3K/AKT/mTOR (PAM) pathway by binding to all class I PI3K isoforms and both mTORC1 and mTORC2 complexes. This mechanism of action and its pharmacokinetic properties distinguish it from other approved and investigational therapies that target PI3Kα, AKT, or mTORC1 individually or in combination. The company has completed enrollment for its Phase 3 clinical trial, VIKTORIA-1, which evaluates gedatolisib alongside fulvestrant, with or without palbociclib, in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC). Detailed results for cohort 1 (patients with PIK3CA wild-type (WT) tumors) have been reported, and enrollment for cohort 2 (patients with PIK3CA mutant-type (MT) tumors) is complete. Additionally, Celcuity Inc. is conducting the Phase 3 clinical trial, VIKTORIA-2, which is evaluating gedatolisib in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor and fulvestrant as a first-line treatment for patients with endocrine treatment-resistant HR+/HER2- ABC.

Celcuity Inc. (NASDAQ:CELC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 38 items for CELC at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Celcuity Announces Preliminary $400M Convertible Senior Notes Offering to Repay Secured Debt and Fund Operations
  • Celcuity Shares Plunge 25% as Breast Cancer Drug Data Disappoints Investors
  • Celcuity's Gedatolisib Doubles PFS to 11.3 Months in Breast Cancer Trial
  • Celcuity's Gedatolisib Shows Superior Efficacy in Phase 3 Breast Cancer Trial
  • Stockholders Approve New Equity Incentive Plan and Expanded ESPP

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$177.04M
Diluted EPS
-$3.79
Op. Cash Flow
-$153.28M
Free Cash Flow
-$153.53M
Operating Income
-$172.19M
Cash & Equivalents
$165.7M
Total Debt
$195.32M
Debt / Equity
1.94×
Shares Outstanding
48.24M sh
Source: 10-K · filed 2026-03-26 · accession 0001493152-26-012801
$53.35
52-week range · as of 2026-11-05 $53.35 – $151.02
Market cap
$2.62B
Volume
636.5K (0.4× avg)
3-mo avg 1.4M
Live data · 2026-11-22 12:45 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CELC - Filings & News (Page 2)

CELC
Jun 03, 2026, 7:16 AM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $93.85
Real-time Price: $53.35 info
Change: -$40.50 (-43%) info
Market Cap: $2.621B info
CELC
Jun 02, 2026, 1:17 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $92.00
Real-time Price: $53.35 info
Change: -$38.65 (-42%) info
Market Cap: $2.621B info
CELC
Jun 02, 2026, 8:13 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $92.00
Real-time Price: $53.35 info
Change: -$38.65 (-42%) info
Market Cap: $2.621B info
CELC
Jun 02, 2026, 8:10 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $91.98
Real-time Price: $53.35 info
Change: -$38.63 (-42%) info
Market Cap: $2.621B info
CELC
May 18, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $132.18
Real-time Price: $53.35 info
Change: -$78.83 (-60%) info
Market Cap: $2.621B info
CELC
May 14, 2026, 5:15 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $138.87
Real-time Price: $53.35 info
Change: -$85.52 (-62%) info
Market Cap: $2.621B info
CELC
May 14, 2026, 4:11 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $129.58
Real-time Price: $53.35 info
Change: -$76.23 (-59%) info
Market Cap: $2.621B info
CELC
May 14, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $129.58
Real-time Price: $53.35 info
Change: -$76.23 (-59%) info
Market Cap: $2.621B info
CELC
May 14, 2026, 11:45 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $133.47
Real-time Price: $53.35 info
Change: -$80.12 (-60%) info
Market Cap: $2.621B info
CELC
May 14, 2026, 7:35 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $127.30
Real-time Price: $53.35 info
Change: -$73.95 (-58%) info
Market Cap: $2.621B info
CELC
May 01, 2026, 5:10 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $140.00
Real-time Price: $53.35 info
Change: -$86.65 (-62%) info
Market Cap: $2.621B info
CELC
May 01, 2026, 5:03 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $125.65
Real-time Price: $53.35 info
Change: -$72.30 (-58%) info
Market Cap: $2.621B info
CELC
Mar 26, 2026, 7:30 AM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $108.00
Real-time Price: $53.35 info
Change: -$54.65 (-51%) info
Market Cap: $2.621B info
CELC
Mar 25, 2026, 4:13 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $106.01
Real-time Price: $53.35 info
Change: -$52.66 (-50%) info
Market Cap: $2.621B info
CELC
Mar 25, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $106.01
Real-time Price: $53.35 info
Change: -$52.66 (-50%) info
Market Cap: $2.621B info
CELC
Mar 24, 2026, 4:06 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $102.01
Real-time Price: $53.35 info
Change: -$48.66 (-48%) info
Market Cap: $2.621B info
CELC
Feb 12, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $104.87
Real-time Price: $53.35 info
Change: -$51.52 (-49%) info
Market Cap: $2.621B info
CELC
Jan 09, 2026, 4:30 PM EST
Filing Type: S-3ASR
Importance Score:
7
Price at Filing: $107.51
Real-time Price: $53.35 info
Change: -$54.16 (-50%) info
Market Cap: $2.621B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets